Purchase this article with an account.
Bruno Esporcatte, Camila Netto, Thais Tanno, Luiz Alberto Melo, Ivan Tavares, Christiane Rolim de Moura; Ahmed glaucoma valve FP7 and FP8 in pediatric glaucoma: A randomized clinical trial. Invest. Ophthalmol. Vis. Sci. 2013;54(15):4487. doi: https://doi.org/.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To compare the results of two models of Ahmed Glaucoma Valve (AGV) (New World Medical, Rancho Cucamonga, CA) implants (FP7 and FP8) in patients with pediatric glaucoma.
A prospective, randomized, clinical trial was carried out. Patients with primary or secondary pediatric glaucoma who previously underwent anti-glaucoma surgery were enrolled. The patients were randomly allocated to receive either FP7 or FP8 AGV model and were examined under general anesthesia just before and 6 months after glaucoma implant surgery.
A total of 8 patients (8 eyes) received FP7 implants and 7 patients (7 eyes) received FP8 implants. The mean (standard deviaton) age of the FP7 and FP8 groups was 4.9 (3.8) years and 4.7 (2.9) years, respectively. No statistically significance differences in intraocular pressure, axial length, corneal diameter and limbus-plate distance were found between groups at the 6-month postoperative visit (p>0.05, Table).
There is no significant difference in the 6-month follow-up of anti-glaucoma surgery using FP7 and FP8 AGV model in pediatric glaucoma.
This PDF is available to Subscribers Only